drug approval

Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year

Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker's obesity drug Qnexa yesterday. Investors are hoping that the FDA's rejection, which includes a request for more safety data -- not another clinical trial -- will lead to approval next year.

AstraZeneca, Pozen Near E.U. Approval for Arthritis Drug

AstraZeneca and Pozen announced Monday that their pain reliever Vimovo for the treatment of arthritis had received positive agreement for approval by the 23 E.U. nations. Vimovo is a combination drug that reduces the risk of ulcers for frequent NSAID users.